Literature DB >> 3316490

A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice.

F R Schneier1, S G Siris.   

Abstract

We reviewed studies measuring unsupervised use of psychoactive substances in schizophrenic and control populations and organized the results by substance class. Despite much variation in their methodologies, these studies broadly agreed that schizophrenic groups' use of amphetamines and cocaine, cannabis, hallucinogens, inhalants, caffeine, and tobacco was significantly greater than or equal to use by control groups consisting of other psychiatric patients or normal subjects. Schizophrenic groups' use of alcohol, opiates, and sedative-hypnotics was significantly less than or equal to use by control groups. We discuss the implications of this nonrandom pattern of drug choice for the hypothesis of substance abuse as a form of self-medication in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3316490     DOI: 10.1097/00005053-198711000-00001

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  43 in total

1.  Use of potentially abusive psychotropic substances in psychiatric inpatients.

Authors:  J Modestin; C Nussbaumer; K Angst; P Scheidegger; D Hell
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 2.  The psychiatric emergency service: where we've been and where we're going.

Authors:  R E Breslow; B J Erickson; K C Cavanaugh
Journal:  Psychiatr Q       Date:  2000

3.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

Review 4.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 5.  Homers regulate drug-induced neuroplasticity: implications for addiction.

Authors:  Karen K Szumlinski; Alexis W Ary; Kevin D Lominac
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

6.  Association between cannabis use, psychosis, and schizotypal personality disorder: findings from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Glen P Davis; Michael T Compton; Shuai Wang; Frances R Levin; Carlos Blanco
Journal:  Schizophr Res       Date:  2013-11-05       Impact factor: 4.939

7.  Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats.

Authors:  Maria Sabrina Spano; Liana Fattore; Francesca Cadeddu; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2012-08-19       Impact factor: 4.530

8.  Patterns, predictors and gender differences in HIV risk among severely mentally ill men and women.

Authors:  L L Otto-Salaj; T G Heckman; L Y Stevenson; J A Kelly
Journal:  Community Ment Health J       Date:  1998-04

Review 9.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

10.  Reasons for smoking among individuals with schizophrenia.

Authors:  Magdalena Galazyn; Marc L Steinberg; Kunal K Gandhi; Megan Piper; Jill M Williams
Journal:  Schizophr Res       Date:  2010-01-06       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.